Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis.
Brain metastasis
Immunotherapy
Melanoma
Stereotactic radiosurgery
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
14 Feb 2020
14 Feb 2020
Historique:
received:
17
12
2019
accepted:
04
02
2020
entrez:
16
2
2020
pubmed:
16
2
2020
medline:
31
10
2020
Statut:
epublish
Résumé
There is limited data on the use of targeted or immunotherapy (TT/IT) in combination with single fraction stereotactic radiosurgery (SRS) in patients with melanoma brain metastasis (MBM). Therefore, we analyzed the outcome and toxicity of SRS alone compared to SRS in combination with TT/IT. Patients with MBM treated with single session SRS at our department between 2014 and 2017 with a minimum follow-up of 3 months after first SRS were included. The primary endpoint of this study was local control (LC). Secondary endpoints were distant intracranial control, radiation necrosis-free survival (RNFS), and overall survival (OS). The local/ distant intracranial control rates, RNFS and OS were analyzed using the Kaplan-Meier method. The log-rank test was used to test differences between groups. Cox proportional hazard model was performed for univariate continuous variables and multivariate analyses. Twenty-eight patients (17 male and 11 female) with 52 SRS-lesions were included. The median follow-up was 19 months (range 14-24 months) after first SRS. Thirty-six lesions (69.2%) were treated with TT/IT simultaneously (4 weeks before and 4 weeks after SRS), while 16 lesions (30.8%) were treated with SRS alone or with sequential TT/IT. The 1-year local control rate was 100 and 83.3% for SRS with TT/IT and SRS alone (p = 0.023), respectively. The estimated 1-year RNFS was 90.0 and 82.1% for SRS in combination with TT/IT and SRS alone (p = 0.935). The distant intracranial control rate after 1 year was 47.7 and 50% for SRS in combination with TT/IT and SRS alone (p = 0.933). On univariate analysis, the diagnosis-specific Graded Prognostic Assessment including the BRAF status (Melanoma-molGPA) was associated with a significantly improved LC. Neither gender nor SRS-PTV margin had a prognostic impact on LC. V10 and V12 were significantly associated with RNFS (p < 0.001 and p = 0.004). SRS with simultaneous TT/IT significantly improved LC with no significant difference in radiation necrosis rate. The therapy combination appears to be effective and safe. However, prospective studies on SRS with simultaneous TT/IT are necessary and ongoing. The institutional review board approved this analysis on 10th of February 2015 and all patients signed informed consent (UE nr. 128-14).
Sections du résumé
BACKGROUND
BACKGROUND
There is limited data on the use of targeted or immunotherapy (TT/IT) in combination with single fraction stereotactic radiosurgery (SRS) in patients with melanoma brain metastasis (MBM). Therefore, we analyzed the outcome and toxicity of SRS alone compared to SRS in combination with TT/IT.
METHODS
METHODS
Patients with MBM treated with single session SRS at our department between 2014 and 2017 with a minimum follow-up of 3 months after first SRS were included. The primary endpoint of this study was local control (LC). Secondary endpoints were distant intracranial control, radiation necrosis-free survival (RNFS), and overall survival (OS). The local/ distant intracranial control rates, RNFS and OS were analyzed using the Kaplan-Meier method. The log-rank test was used to test differences between groups. Cox proportional hazard model was performed for univariate continuous variables and multivariate analyses.
RESULTS
RESULTS
Twenty-eight patients (17 male and 11 female) with 52 SRS-lesions were included. The median follow-up was 19 months (range 14-24 months) after first SRS. Thirty-six lesions (69.2%) were treated with TT/IT simultaneously (4 weeks before and 4 weeks after SRS), while 16 lesions (30.8%) were treated with SRS alone or with sequential TT/IT. The 1-year local control rate was 100 and 83.3% for SRS with TT/IT and SRS alone (p = 0.023), respectively. The estimated 1-year RNFS was 90.0 and 82.1% for SRS in combination with TT/IT and SRS alone (p = 0.935). The distant intracranial control rate after 1 year was 47.7 and 50% for SRS in combination with TT/IT and SRS alone (p = 0.933). On univariate analysis, the diagnosis-specific Graded Prognostic Assessment including the BRAF status (Melanoma-molGPA) was associated with a significantly improved LC. Neither gender nor SRS-PTV margin had a prognostic impact on LC. V10 and V12 were significantly associated with RNFS (p < 0.001 and p = 0.004).
CONCLUSION
CONCLUSIONS
SRS with simultaneous TT/IT significantly improved LC with no significant difference in radiation necrosis rate. The therapy combination appears to be effective and safe. However, prospective studies on SRS with simultaneous TT/IT are necessary and ongoing.
TRIAL REGISTRATION
BACKGROUND
The institutional review board approved this analysis on 10th of February 2015 and all patients signed informed consent (UE nr. 128-14).
Identifiants
pubmed: 32059731
doi: 10.1186/s13014-020-1485-8
pii: 10.1186/s13014-020-1485-8
pmc: PMC7023694
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Références
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):187-94
pubmed: 16814946
Eur J Cancer. 2019 Mar;110:11-20
pubmed: 30739835
Radiol Med. 2016 Jan;121(1):60-9
pubmed: 26231251
Radiother Oncol. 2019 Mar;132:70-78
pubmed: 30825972
Lancet Oncol. 2017 Jul;18(7):863-873
pubmed: 28592387
Lancet Oncol. 2012 May;13(5):459-65
pubmed: 22456429
Curr Pharmacol Rep. 2016 Dec;2(6):309-325
pubmed: 28546917
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):407-13
pubmed: 25084610
J Neurooncol. 2017 Sep;134(2):433-441
pubmed: 28674974
J Neurooncol. 2015 Oct;125(1):149-56
pubmed: 26307446
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
Radiat Oncol. 2011 May 15;6:48
pubmed: 21575163
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):100-8
pubmed: 25442342
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):368-75
pubmed: 25754629
Curr Probl Cancer. 2011 Jul-Aug;35(4):200-10
pubmed: 21911183
J Immunother Cancer. 2019 Apr 11;7(1):102
pubmed: 30975225
Radiother Oncol. 2019 Jan;130:104-112
pubmed: 30241791
World Neurosurg. 2017 Apr;100:632-640.e4
pubmed: 28179176
J Clin Oncol. 2014 Dec 1;32(34):3810-6
pubmed: 25349290
Am J Clin Oncol. 2017 Oct;40(5):444-450
pubmed: 26017484
Cancer. 2016 Oct;122(19):3051-8
pubmed: 27285122
J Neurosurg. 1998 Jan;88(1):11-20
pubmed: 9420067
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):812-816
pubmed: 29063850
Eur J Cancer. 2017 Apr;75:169-178
pubmed: 28236768
Cancer Treat Rev. 2017 Feb;53:25-37
pubmed: 28056412
Adv Radiat Oncol. 2017 Aug 12;2(4):572-580
pubmed: 29204524
Eur J Cancer. 2017 Oct;84:44-54
pubmed: 28783540
Ann Oncol. 2016 Mar;27(3):434-41
pubmed: 26712903
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925
pubmed: 29485071
Strahlenther Onkol. 2020 Jan;196(1):70-76
pubmed: 31586230
J Neurosurg. 2017 Nov;127(5):1007-1014
pubmed: 28059663
Radiat Oncol. 2019 Jun 11;14(1):103
pubmed: 31186023